NCT07125547 - Neoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 5, 2025

Primary Completion Date

December 30, 2026

Study Completion Date

December 30, 2030

Conditions

Ureteral CancerNeoadjuvant TherapyPD-1 InhibitorKidney-sparingTislelizumabNab-paclitaxel

Interventions

DRUG

PD-1 inhibitior

Tislelizumab 200mg iv will be administered on Day 1 every 3 weeks for 2-3 cycles.

DRUG

Nab-paclitaxel

Nab-Paclitaxel 125mg/m2 IV will be administered on Day 1 every 3 weeks for 2-3 cycles

PROCEDURE

distal ureterectomy

Distal ureterectomy (Distal ureterectomy + Partial cystectomy +Psoas hitch procedure + Ureteral reimplantation into the bladder + Ipsilateral pelvic lymph node dissection) will be conducted after neoadjuvant treatment.

Trial Locations (1)

300211

RECRUITING

The Second Hospital of Tianjin Medical University, Tianjin

All Listed Sponsors

lead

Tianjin Medical University Second Hospital

OTHER